Reducing mucus production after urinary reconstruction: A prospective randomised trial.

James Michael Olu N'Dow, C. N. Robson, J. N. S. Matthews, D. E. Neal, J. P. Pearson

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: After transposition into the urinary tract, intestinal segments continue to produce mucus. We determine the effectiveness of muco-regulatory drugs, including N-acetylcysteine, aspirin and ranitidine, in reducing mucus secretion and urine viscosity in patients with transposed segments.

Materials and Methods: Our trial was a prospective randomized, double-blind placebo controlled crossover study involving 12 patients who underwent ileal conduit and 31 who underwent bladder reconstruction, Each treatment lasted 3 weeks with a a-week washout. Pretreatment and posttreatment 24-hour urine samples were analyzed for mucin and viscosity after papain digestion, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and periodic acid-Schiff assay. A disease specific questionnaire and SF-36 quality of life survey were completed.

Results: According to the questionnaire, mucus production did not decrease with time in 67% of patients. Mucin comprised 3% of the total nondialyzable material in urine (65 mg./24-hour for ileal conduit and 60 mg,/24-hour for bladder reconstruction). Analysis of questionnaires and laboratory results failed to demonstrate any benefit of taking muco-regulatory agents compared with placebo.

Conclusions: The use of N-acetylcysteine, aspirin and ranitidine did not result in a reduction in mucin production, urine viscosity or improvement in quality of life.

Original languageEnglish
Pages (from-to)1433-1440
Number of pages7
JournalJournal of Urology
Volume165
Issue number5
DOIs
Publication statusPublished - 2001

Keywords

  • mucus
  • expectorants
  • acetylcysteine
  • aspirin
  • ranitidine
  • HUMAN GALL-BLADDER
  • TRACT RECONSTRUCTION
  • ILEAL NEOBLADDER
  • ACETYLCYSTEINE
  • GLYCOPROTEIN
  • MUCIN
  • ENTEROCYSTOPLASTY
  • AUGMENTATION
  • DISSOLUTION
  • CYSTOPLASTY

Cite this

Reducing mucus production after urinary reconstruction: A prospective randomised trial. / N'Dow, James Michael Olu; Robson, C. N.; Matthews, J. N. S.; Neal, D. E.; Pearson, J. P.

In: Journal of Urology, Vol. 165, No. 5, 2001, p. 1433-1440.

Research output: Contribution to journalArticle

N'Dow, James Michael Olu ; Robson, C. N. ; Matthews, J. N. S. ; Neal, D. E. ; Pearson, J. P. / Reducing mucus production after urinary reconstruction: A prospective randomised trial. In: Journal of Urology. 2001 ; Vol. 165, No. 5. pp. 1433-1440.
@article{52af2367dc944ed4bfe89cbccaa27811,
title = "Reducing mucus production after urinary reconstruction: A prospective randomised trial.",
abstract = "Purpose: After transposition into the urinary tract, intestinal segments continue to produce mucus. We determine the effectiveness of muco-regulatory drugs, including N-acetylcysteine, aspirin and ranitidine, in reducing mucus secretion and urine viscosity in patients with transposed segments.Materials and Methods: Our trial was a prospective randomized, double-blind placebo controlled crossover study involving 12 patients who underwent ileal conduit and 31 who underwent bladder reconstruction, Each treatment lasted 3 weeks with a a-week washout. Pretreatment and posttreatment 24-hour urine samples were analyzed for mucin and viscosity after papain digestion, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and periodic acid-Schiff assay. A disease specific questionnaire and SF-36 quality of life survey were completed.Results: According to the questionnaire, mucus production did not decrease with time in 67{\%} of patients. Mucin comprised 3{\%} of the total nondialyzable material in urine (65 mg./24-hour for ileal conduit and 60 mg,/24-hour for bladder reconstruction). Analysis of questionnaires and laboratory results failed to demonstrate any benefit of taking muco-regulatory agents compared with placebo.Conclusions: The use of N-acetylcysteine, aspirin and ranitidine did not result in a reduction in mucin production, urine viscosity or improvement in quality of life.",
keywords = "mucus, expectorants, acetylcysteine, aspirin, ranitidine, HUMAN GALL-BLADDER, TRACT RECONSTRUCTION, ILEAL NEOBLADDER, ACETYLCYSTEINE, GLYCOPROTEIN, MUCIN, ENTEROCYSTOPLASTY, AUGMENTATION, DISSOLUTION, CYSTOPLASTY",
author = "N'Dow, {James Michael Olu} and Robson, {C. N.} and Matthews, {J. N. S.} and Neal, {D. E.} and Pearson, {J. P.}",
year = "2001",
doi = "10.1016/S0022-5347(05)66323-9",
language = "English",
volume = "165",
pages = "1433--1440",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Reducing mucus production after urinary reconstruction: A prospective randomised trial.

AU - N'Dow, James Michael Olu

AU - Robson, C. N.

AU - Matthews, J. N. S.

AU - Neal, D. E.

AU - Pearson, J. P.

PY - 2001

Y1 - 2001

N2 - Purpose: After transposition into the urinary tract, intestinal segments continue to produce mucus. We determine the effectiveness of muco-regulatory drugs, including N-acetylcysteine, aspirin and ranitidine, in reducing mucus secretion and urine viscosity in patients with transposed segments.Materials and Methods: Our trial was a prospective randomized, double-blind placebo controlled crossover study involving 12 patients who underwent ileal conduit and 31 who underwent bladder reconstruction, Each treatment lasted 3 weeks with a a-week washout. Pretreatment and posttreatment 24-hour urine samples were analyzed for mucin and viscosity after papain digestion, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and periodic acid-Schiff assay. A disease specific questionnaire and SF-36 quality of life survey were completed.Results: According to the questionnaire, mucus production did not decrease with time in 67% of patients. Mucin comprised 3% of the total nondialyzable material in urine (65 mg./24-hour for ileal conduit and 60 mg,/24-hour for bladder reconstruction). Analysis of questionnaires and laboratory results failed to demonstrate any benefit of taking muco-regulatory agents compared with placebo.Conclusions: The use of N-acetylcysteine, aspirin and ranitidine did not result in a reduction in mucin production, urine viscosity or improvement in quality of life.

AB - Purpose: After transposition into the urinary tract, intestinal segments continue to produce mucus. We determine the effectiveness of muco-regulatory drugs, including N-acetylcysteine, aspirin and ranitidine, in reducing mucus secretion and urine viscosity in patients with transposed segments.Materials and Methods: Our trial was a prospective randomized, double-blind placebo controlled crossover study involving 12 patients who underwent ileal conduit and 31 who underwent bladder reconstruction, Each treatment lasted 3 weeks with a a-week washout. Pretreatment and posttreatment 24-hour urine samples were analyzed for mucin and viscosity after papain digestion, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and periodic acid-Schiff assay. A disease specific questionnaire and SF-36 quality of life survey were completed.Results: According to the questionnaire, mucus production did not decrease with time in 67% of patients. Mucin comprised 3% of the total nondialyzable material in urine (65 mg./24-hour for ileal conduit and 60 mg,/24-hour for bladder reconstruction). Analysis of questionnaires and laboratory results failed to demonstrate any benefit of taking muco-regulatory agents compared with placebo.Conclusions: The use of N-acetylcysteine, aspirin and ranitidine did not result in a reduction in mucin production, urine viscosity or improvement in quality of life.

KW - mucus

KW - expectorants

KW - acetylcysteine

KW - aspirin

KW - ranitidine

KW - HUMAN GALL-BLADDER

KW - TRACT RECONSTRUCTION

KW - ILEAL NEOBLADDER

KW - ACETYLCYSTEINE

KW - GLYCOPROTEIN

KW - MUCIN

KW - ENTEROCYSTOPLASTY

KW - AUGMENTATION

KW - DISSOLUTION

KW - CYSTOPLASTY

U2 - 10.1016/S0022-5347(05)66323-9

DO - 10.1016/S0022-5347(05)66323-9

M3 - Article

VL - 165

SP - 1433

EP - 1440

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -